In July 2024, doctors at Berlin's Charite hospital announced something remarkable: a 60-year-old man had been completely cleared of HIV — without a trace of the virus detectable in his body, despite not taking antiretroviral medication for over five years. Almost simultaneously, a clinical trial in Africa reported that a new injectable drug had achieved 100% efficacy in preventing HIV infection — zero new cases among thousands of participants.
These headlines naturally raise a question: is humanity finally defeating HIV?
The answer is nuanced. The cure cases remain extraordinary — achieved through dangerous procedures that cannot be scaled to the 39 million people currently living with HIV worldwide. But the prevention breakthroughs are genuinely transformative, with the potential to change the trajectory of the epidemic for millions. And in between, antiretroviral therapy has already turned what was once a death sentence into a manageable chronic condition with near-normal life expectancy.
This article walks through the real science behind each of these developments — what is actually happening, why it matters, and what it means for the future.
Why HIV Is So Hard to Eliminate
To understand why curing HIV remains so difficult, you need to understand how the virus operates at the molecular level.
HIV is a retrovirus, which means it does something most pathogens cannot: it integrates its genetic material directly into the DNA of its host's cells. Once HIV infects a CD4+ T cell (a critical component of the immune system), the virus uses an enzyme called reverse transcriptase to convert its RNA genome into DNA, and another enzyme called integrase to splice that DNA into the human chromosome.
At that point, the viral DNA becomes part of the cell's own genome. It can sit there silently for years — even decades — in what researchers call the latent reservoir. The cell may divide and produce daughter cells, each carrying the viral DNA. The immune system cannot distinguish these cells from healthy ones because the virus is not actively producing viral proteins that would trigger an immune response.
This is the fundamental challenge. Antiretroviral therapy (ART) works brilliantly at preventing the virus from replicating — it blocks the enzymes HIV needs to copy itself and infect new cells. When a person takes ART consistently, viral load drops to undetectable levels, the immune system recovers, and the person can live a normal lifespan. But ART cannot reach the integrated viral DNA hiding inside resting cells. The moment therapy stops, those reservoirs reactivate and the virus comes roaring back.
Estimates suggest that even a person with an undetectable viral load on ART may harbor millions of cells containing integrated HIV DNA. Eliminating every single one of those cells is the barrier that has made a true cure so elusive.
The Berlin Patients: How Stem Cell Transplants Cured HIV
The first confirmed cure of HIV was not the result of an antiviral drug or a vaccine. It was a side effect of cancer treatment.
In 2007, Timothy Ray Brown — later known as the "Berlin Patient" — was living with HIV and undergoing treatment for acute myeloid leukemia at Charite hospital in Berlin. His oncologist, Dr. Gero Hutter, had an idea: since Brown needed a stem cell transplant to treat his leukemia, what if the donor was someone who was naturally resistant to HIV?
About 1% of people of European descent carry a genetic mutation called CCR5-delta32. The CCR5 protein sits on the surface of CD4+ T cells, and most strains of HIV use it as a co-receptor — essentially a doorknob they grab to enter the cell. People who carry two copies of the delta32 mutation (homozygous) produce a defective CCR5 protein that HIV cannot bind to, making them essentially immune to the most common HIV strains.
Dr. Hutter found a bone marrow donor who was both a tissue match for Brown and homozygous for CCR5-delta32. The transplant procedure involved first destroying Brown's own immune system with chemotherapy and radiation — standard practice for leukemia treatment — and then rebuilding it with the donor's stem cells.
The result was extraordinary. The chemotherapy killed Brown's existing immune cells, including those harboring the latent HIV reservoir. The new immune system, grown from donor stem cells carrying the CCR5-delta32 mutation, was resistant to HIV reinfection. Brown stopped taking antiretroviral therapy, and the virus never came back. He lived HIV-free until his death from leukemia recurrence in 2020.
The Next Berlin Patient and Others: Proving It Wasn't a Fluke
For years, Brown's case was considered a one-off miracle. Then the cases started accumulating.
In 2020, Adam Castillejo — the "London Patient" — was confirmed cured through a similar procedure. Like Brown, he had received a stem cell transplant from a CCR5-delta32 homozygous donor to treat Hodgkin's lymphoma. After stopping ART, his viral load remained undetectable. Extensive testing found no replication-competent virus.
A similar case was described in Dusseldorf around the same period, adding to the evidence.
Then came the announcement from Charite in July 2024 — the next "Berlin Patient." This case had an important twist. The 60-year-old man, who had been HIV-positive since at least 2009, developed acute myeloid leukemia in 2015. When doctors searched for a donor, they could not find anyone in their registry who was homozygous for CCR5-delta32 and also a tissue match.
Instead, they found a compromise: a donor who was heterozygous for the mutation — carrying one normal copy and one mutant copy of the CCR5 gene. This was significant because heterozygous carriers are not fully resistant to HIV; they still produce some functional CCR5 protein.
Nevertheless, the combination of chemotherapy (which destroyed the existing reservoir) and the transplant (which provided a partially resistant immune system) proved sufficient. After more than five years without antiretroviral therapy, no trace of HIV was found. The Charite team declared it a cure.
This case expanded what researchers thought was possible. If even a heterozygous donor could lead to a cure, the mechanisms involved might be more complex — and potentially more exploitable — than simply replacing the CCR5 receptor.
Why Stem Cell Transplants Cannot Be the Answer for Everyone
With at least four confirmed cures through stem cell transplantation, a natural question arises: why not offer this to all 39 million people living with HIV?
The answer comes down to three hard realities.
First, the procedure is genuinely dangerous. Stem cell transplantation involves obliterating the patient's entire immune system with chemotherapy and/or radiation before rebuilding it from donor cells. This process carries a mortality rate of 10-30% depending on the patient's condition and the degree of tissue mismatch. Even successful transplants involve months of extreme vulnerability to infections, graft-versus-host disease (where the new immune system attacks the patient's body), and long-term organ damage.
For someone who is otherwise healthy and managing HIV effectively with daily medication, this risk is unacceptable. Every person cured through transplantation had a life-threatening cancer that independently required the procedure — HIV clearance was a beneficial side effect, not the primary goal.
Second, finding suitable donors is extraordinarily difficult. A donor must be a close tissue match (HLA-compatible) to avoid fatal graft rejection. Adding the CCR5-delta32 requirement narrows the pool dramatically. The mutation is largely confined to Northern European populations, making it essentially unavailable for the vast majority of people living with HIV in sub-Saharan Africa and Southeast Asia, where the epidemic is concentrated.
Third, modern ART has made the risk-benefit calculation clear. A person who consistently takes antiretroviral therapy today can expect a near-normal life expectancy, with viral load suppressed to undetectable levels. They cannot transmit the virus sexually (a principle known as U=U, or Undetectable = Untransmittable). The quality of life on modern single-pill, once-daily regimens is dramatically different from the multi-drug cocktails of the 1990s.
As one HIV clinician put it: we would not recommend heart transplantation to someone whose heart disease is perfectly managed with medication. The same logic applies here.
Beyond Transplants: Other Approaches to a Cure
If stem cell transplantation is too risky for widespread use, researchers have been pursuing alternatives that could clear the latent reservoir without destroying the immune system.
Shock and Kill (Latency Reversal)
The most extensively studied approach is called "shock and kill" (also known as "kick and kill"). The idea is to use drugs that force the latent HIV to activate — shocking it out of hiding — so the immune system (or additional therapies) can find and destroy the infected cells. Several classes of latency-reversing agents have been tested in clinical trials, including histone deacetylase inhibitors (HDACi) like vorinostat and panobinostat.
The challenge: while these drugs can measurably reactivate latent virus, the resulting immune response has not been strong enough to significantly reduce the reservoir in most trials. The "shock" part works, but the "kill" part remains incomplete.
Broadly Neutralizing Antibodies (bNAbs)
Another promising avenue involves broadly neutralizing antibodies — highly specialized immune proteins that can recognize and neutralize a wide range of HIV variants. Unlike the antibodies most people's immune systems produce, which target a narrow range of viral strains, bNAbs target conserved regions of the virus that it cannot easily mutate away from.
Recent research has shown significant progress in engineering bNAbs that last longer in the body and cover more viral variants. Some trials are testing whether periodic bNAb infusions could replace daily antiretroviral pills, while others are exploring whether combinations of bNAbs could help clear the reservoir when used alongside latency-reversing agents.
Gene Therapy and CRISPR
Perhaps the most futuristic approach: using gene-editing tools like CRISPR-Cas9 to either cut the integrated HIV DNA out of host cells or modify a person's own CCR5 genes to mimic the natural delta32 mutation. Early-phase research has demonstrated proof of concept in laboratory settings and animal models, but delivering the gene-editing machinery to enough cells in a living human remains a formidable technical challenge.
None of these approaches has produced a cure in a clinical trial yet, but collectively they represent serious scientific programs with growing investment and incremental progress.
The Real Game-Changer: Prevention With Lenacapavir
While the cure research captures headlines, the most impactful development in HIV science in 2024 may be something different entirely: a prevention drug that achieved perfect efficacy in a large clinical trial.
Lenacapavir, developed by Gilead Sciences, is a first-in-class capsid inhibitor. It works by a fundamentally different mechanism than any previous antiretroviral: it targets the protein shell (capsid) of the virus at multiple stages of its lifecycle, rather than focusing on a single enzyme like older drugs.
What makes lenacapavir remarkable for prevention is its pharmacokinetics: a single subcutaneous injection provides sustained drug levels for six months. This means that instead of taking a daily pill, a person could receive two injections per year and be protected against HIV.
The drug was first approved by the FDA in December 2022 for treatment of multi-drug-resistant HIV — a last resort for patients whose virus had developed resistance to other medications. But its potential as a prevention tool (pre-exposure prophylaxis, or PrEP) is what generated the global excitement.
PURPOSE 1: Zero Infections Among Thousands
The pivotal study, called PURPOSE 1, enrolled more than 5,300 women aged 16-25 across clinical sites in South Africa and Uganda — regions with some of the highest HIV incidence rates in the world. Participants were randomized to one of three groups: lenacapavir injections every six months, daily oral Truvada (the standard PrEP pill), or daily oral Descovy (a newer PrEP pill).
The results, published in the New England Journal of Medicine, were unprecedented. In the lenacapavir group: zero HIV infections. None. Among the 2,134 women who received twice-yearly lenacapavir injections, not a single case of HIV seroconversion was recorded. The HIV incidence rate was 0.00 per 100 person-years.
By comparison, the background incidence rate in this population (what would be expected without any PrEP) was approximately 2.41 per 100 person-years. Even the oral PrEP groups, which are already effective when taken consistently, had lower-than-expected but still non-zero infection rates.
Full safety data presented at AIDS 2024 showed that the injection was generally well-tolerated. The most common side effects were injection-site reactions (pain, swelling, or nodules), which were mostly mild and resolved without intervention.
The significance cannot be overstated: this is the first PrEP agent to demonstrate 100% efficacy in a phase 3 trial.
How Lenacapavir Works: Molecular Precision
Lenacapavir's mechanism of action is genuinely novel. All previous antiretroviral drugs target one of three viral enzymes: reverse transcriptase (which converts viral RNA to DNA), integrase (which splices viral DNA into the host genome), or protease (which processes viral proteins into their functional forms). Lenacapavir targets none of these.
Instead, it targets the capsid — the protein shell made of approximately 1,500 copies of the p24 protein that encases the virus's genetic material. The capsid is not just passive packaging; it plays active roles in multiple stages of the HIV lifecycle, including nuclear entry, reverse transcription, integration, and viral assembly.
Detailed structural studies published in Nature revealed how lenacapavir works at the atomic level. The molecule fits precisely into grooves formed at the junctions between p24 molecules in the capsid lattice. It makes seven hydrogen bonds and several electrostatic contacts, essentially locking itself into place with a binding affinity that is orders of magnitude stronger than other antiretroviral drugs.
This exceptionally tight binding is what enables the six-month dosing interval. Because the drug binds so strongly to its target, very low concentrations are sufficient for full antiviral activity. A single injection creates a drug depot under the skin that slowly releases lenacapavir over months, maintaining protective levels throughout.
The original chemical scaffold was identified in a Gilead patent filed in 2018, with the clinical candidate emerging from years of optimization to maximize binding affinity, metabolic stability, and the slow-release pharmacokinetic profile.
The Evolution of PrEP: From Daily Pills to Twice-Yearly Injections
Lenacapavir did not emerge in a vacuum. It represents the latest step in a progression of HIV prevention tools that have been steadily improving for over a decade.
2012: Daily Oral PrEP
The first PrEP option — a daily pill combining tenofovir and emtricitabine (Truvada) — was approved by the WHO and the FDA for HIV prevention. When taken consistently, it reduced the risk of HIV infection by up to 99%. The keyword is "consistently" — real-world effectiveness was significantly lower because adherence to a daily pill regimen is difficult, especially among young people and populations facing stigma.
2020: The Dapivirine Vaginal Ring
Recognizing that pills were not ideal for everyone, researchers developed a monthly vaginal ring containing the antiretroviral dapivirine. Clinical trials showed it reduced HIV risk by 27-35% — less effective than oral PrEP at peak adherence, but offering a discreet option that did not require daily action. The WHO recommended it as an additional prevention choice for women at substantial risk.
2021: Long-Acting Injectable Cabotegravir
A major leap came with cabotegravir, an integrase inhibitor delivered as an intramuscular injection every two months. The landmark HPTN 084 trial showed that injectable cabotegravir was 89% more effective than daily oral Truvada at preventing HIV in women — not because the drug was inherently more potent, but because injections every two months eliminate the adherence barrier of remembering a daily pill.
However, cabotegravir access has been severely limited by cost and distribution challenges. Manufacturer ViiV Healthcare has faced criticism for the speed of rollout in the low- and middle-income countries that need it most.
2024: Lenacapavir and the PURPOSE Trials
Lenacapavir extends the injection interval from every two months to every six months — and does so with unprecedented efficacy data. A second trial, PURPOSE 2, is testing the drug in cisgender men, transgender individuals, and non-binary people, with results expected to inform broader regulatory submissions.
Why Adherence Is the Hidden Key to Everything
If you have followed the progression from daily pills to bimonthly injections to twice-yearly injections, you may have noticed a theme: much of the innovation in HIV prevention is not about making more potent drugs. It is about making it easier for people to actually use them.
This is not a trivial concern. The gap between clinical trial efficacy and real-world effectiveness is one of the most significant challenges in HIV prevention.
Oral PrEP is up to 99% effective when taken daily as prescribed. But in real-world settings, adherence rates drop dramatically. Studies in sub-Saharan Africa have found that young women — the population at highest risk — often discontinue oral PrEP within months. Reasons include forgetfulness, pill fatigue, stigma (being seen taking HIV-related medication can lead to social consequences), and disruption of daily routines.
The UNAIDS Global AIDS Update 2024 highlighted this gap: while oral PrEP has been available for over a decade, uptake remains far below what is needed to bend the epidemic curve, particularly among the young women and adolescent girls in sub-Saharan Africa who account for a disproportionate share of new infections.
This is precisely why a twice-yearly injection is transformative. It removes nearly every adherence barrier:
- No daily routine required
- No pills to store, carry, or be discovered
- No daily reminder of HIV risk
- Only two healthcare visits per year
- No possibility of forgetting a dose between injections
The difference between "a drug that works if you take it every day" and "a drug that works after two visits per year" is not incremental. For populations facing stigma, unstable living situations, or simply the chaos of adolescent life, it could be the difference between a theoretical tool and an actual one.
The Global Picture: Where HIV Stands Today
To understand why these advances matter, it helps to see the current state of the HIV epidemic.
According to UNAIDS data from 2023, approximately 39 million people were living with HIV globally. Of those, about 29.8 million were on antiretroviral therapy — a remarkable achievement considering that ART coverage was below 1% in many of the hardest-hit countries as recently as the early 2000s.
New HIV infections have declined by about 59% from their peak in the mid-1990s, falling to approximately 1.3 million new infections in 2022. AIDS-related deaths have dropped by 69% from their peak, to about 630,000 per year.
But the progress is uneven. Sub-Saharan Africa still accounts for about 65% of all people living with HIV. Young women aged 15-24 in the region are three times more likely to acquire HIV than their male peers. And while treatment coverage is expanding, an estimated 9.2 million people who need ART still do not have access to it.
The WHO updated its clinical guidelines in 2024 to incorporate the latest evidence on treatment regimens, emphasizing dolutegravir-based first-line therapy and expanding recommendations for long-acting options. These guidelines serve as the reference framework for national HIV programs in over 100 countries.
Antiretroviral Therapy: The Quiet Revolution Already Underway
While cure research and PrEP breakthroughs capture public attention, the most impactful revolution in HIV has already happened — and it is the transformation of treatment.
Modern antiretroviral therapy is not the same as the regimens of the 1990s, which required dozens of pills per day, caused severe side effects, and still left many patients with progressive disease. Today's standard first-line therapy typically consists of a single pill taken once daily, combining two or three antiretroviral agents with complementary mechanisms.
The WHO's 2024 guidelines recommend dolutegravir-based regimens as the preferred first-line therapy for almost all adults, adolescents, and children. Dolutegravir is an integrase inhibitor with a high barrier to resistance, excellent tolerability, and once-daily dosing. Combined with a tenofovir/lamivudine or tenofovir/emtricitabine backbone, it suppresses viral load to undetectable levels in the vast majority of patients.
For individuals whose virus develops resistance — a real but manageable challenge, especially in settings where treatment monitoring is limited — newer drugs provide options. Lenacapavir, in its treatment-approved formulation, serves as a critical option for people with multi-drug-resistant HIV who have exhausted other therapeutic classes.
The long-acting treatment landscape is also expanding. Cabenuva (cabotegravir + rilpivirine) is an injectable regimen given every one to two months, already approved in many countries as a complete treatment for virologically suppressed adults — eliminating the need for daily pills entirely.
The net result: a person diagnosed with HIV today, who has access to treatment and takes it consistently, can expect a lifespan that is statistically indistinguishable from someone who is HIV-negative. This is the single most important fact in HIV medicine, and it cannot be stated often enough.
U=U: Undetectable Means Untransmittable
One of the most significant scientific findings of the past decade — and one that has profound implications for stigma reduction — is the concept of U=U: Undetectable = Untransmittable.
Multiple large-scale studies, including the landmark PARTNER 1 and PARTNER 2 trials, followed thousands of mixed-status couples (one partner HIV-positive, one HIV-negative) over years. In couples where the HIV-positive partner was on effective ART with an undetectable viral load, zero HIV transmissions occurred through sexual contact. Not a reduced risk. Zero.
This finding has been endorsed by UNAIDS, the WHO, the CDC, and virtually every major HIV organization worldwide. It means that effective treatment is itself a form of prevention — a concept called Treatment as Prevention (TasP).
The implications extend beyond individual couples. If everyone living with HIV were diagnosed and on effective treatment (the UNAIDS 95-95-95 targets: 95% diagnosed, 95% of those on treatment, 95% of those virally suppressed), the epidemic would effectively end through treatment alone, even without a vaccine or cure.
Progress toward these targets is real but incomplete. Globally, as of 2023, approximately 86% of people living with HIV knew their status, 89% of those were on treatment, and 93% of those were virally suppressed — translating to about 71% of all people with HIV having suppressed viral loads. The gap between 71% and the target of ~86% (which would result from 95-95-95) represents millions of people and is where much of new transmission originates.
Remaining Challenges: Access, Equity, and Stigma
For all the scientific progress, the hardest problems in HIV are not molecular — they are structural.
Access to treatment remains profoundly unequal. While ART coverage exceeds 80% in many countries, others — particularly in West and Central Africa, the Middle East, and Eastern Europe — lag significantly behind. The UNAIDS 2024 report documented that funding for the HIV response in low- and middle-income countries has been declining, threatening the sustainability of treatment programs.
New prevention tools face distribution barriers. Long-acting injectable cabotegravir, despite its superior efficacy over oral PrEP, remains largely unavailable in the countries that need it most due to pricing, supply chain limitations, and the healthcare infrastructure required for regular injections. Whether lenacapavir will face similar barriers is an active area of advocacy, with Gilead facing pressure to ensure affordable access in low-income settings.
Stigma remains a barrier to testing, treatment, and prevention. Fear of discrimination discourages people from getting tested. Concern about being seen at an HIV clinic or carrying HIV medication deters some from starting or continuing treatment. And the stigma attached to populations most affected by HIV — men who have sex with men, sex workers, people who inject drugs, and transgender individuals — compounds the challenge in many cultural contexts.
Criminalization of HIV in many countries creates a hostile legal environment. Laws that criminalize HIV non-disclosure, exposure, or transmission have been shown to discourage testing and engagement with healthcare, achieving the opposite of their stated intent.
These are not problems that a better drug can solve. They require political will, sustained funding, legal reform, and community engagement.
What About a Vaccine?
The HIV vaccine — sometimes called the "holy grail" of HIV research — remains elusive after more than 40 years of effort.
HIV presents unique challenges for vaccine development. The virus mutates at an extraordinary rate, with different strains varying by up to 35% in their envelope protein sequences. It attacks the very immune cells that would normally fight it. And it establishes the latent reservoir so quickly after infection that a vaccine would need to prevent infection entirely, not just control it — a much harder bar to clear.
Several large-scale vaccine trials have failed, most recently the HVTN 702 trial in South Africa (stopped for futility in 2020) and the Mosaico trial (stopped in 2023 after interim analysis showed no efficacy).
However, the field has not given up. New approaches leveraging mRNA technology (the same platform used for COVID-19 vaccines), germline-targeting immunogens (which aim to stimulate the rare B cells capable of producing broadly neutralizing antibodies), and structure-guided antigen design are in early clinical trials. Some researchers believe that the advances in understanding bNAbs — the broadly neutralizing antibodies discussed earlier — could finally crack the vaccine problem by providing a clear immunological target.
But realistically, an effective HIV vaccine remains years to decades away. In the interim, the combination of treatment-as-prevention and the new generation of long-acting PrEP agents may need to carry the burden.
Tracking Your Health: Why Regular Screening Matters
The advances in HIV treatment and prevention are most powerful when combined with regular health monitoring. Early diagnosis remains the single most important factor in HIV outcomes — people who are diagnosed early and start treatment promptly have outcomes nearly identical to HIV-negative individuals.
The WHO recommends that individuals at higher risk be tested for HIV at least annually, and that all adults be tested at least once in their lifetime as part of routine preventive care. Yet many people have never been tested, often because they do not perceive themselves as being at risk — or because testing requires a dedicated trip to a clinic.
WatchMyHealth's physician visit tracker can help you schedule and log regular health screenings, including HIV testing, as part of your overall preventive health routine. The app's preventive screening recommendations take your health profile into account and can remind you when screenings are due. Because the best medical advances in the world only help if you access them.
Beyond HIV specifically, the principle applies broadly: whether it is blood pressure, metabolic markers, cancer screenings, or sexual health, regular monitoring turns late-stage intervention into early prevention. The data is clear that systematic health tracking — supported by tools that make it easy — leads to earlier detection and better outcomes across virtually every condition.
The Bottom Line: Progress, Not Victory
So, is humanity defeating HIV?
The honest answer: we are winning, but we have not won.
The cure cases — the Berlin Patients, the London Patient, and others — are scientific landmarks that prove complete viral clearance is biologically possible. But they rely on procedures too dangerous and too rare to help the vast majority of people living with HIV. Research into scalable cure strategies (gene therapy, latency reversal, broadly neutralizing antibodies) is advancing but has not yet translated into a practical treatment.
The prevention revolution — from daily pills to bimonthly injections to twice-yearly lenacapavir — is genuinely transformative. A drug that achieves 100% efficacy with two injections per year could, if made widely accessible, dramatically reduce new infections in the populations most affected. But accessibility is not a given — it requires pricing commitments, supply chain infrastructure, and political prioritization.
And antiretroviral treatment has already changed the game. HIV is no longer a death sentence; for those with access to modern therapy, it is a manageable chronic condition compatible with a full, healthy life. The challenge is extending that access to the estimated 9 million people who still need it.
The science has delivered remarkable tools. The remaining battles are about equity, access, political will, and the persistence of stigma. These are harder problems than molecular biology — but they are solvable, and solving them would save millions of lives.
Stay engaged with your own health. Get tested. Talk to your doctor about what preventive tools are relevant for you. And if you are living with HIV, know that the science has never been more firmly on your side.
